Effect of NMN on Muscle Recovery and Physical Capacity in Healthy Volunteers With Moderate Physical Activity

Not Applicable

Completed

• Conditions: Physical Activity; Muscle Recovery
• Interventions: Dietary Supplement: Nicotinamide mononucleotide; Other: Placebo

• Registration Number: NCT04664361
• Lead Sponsor: Seneque SA

Brief Summary

The purpose of this study is to evaluate the effect of NMN supplementation (250 and 500 mg/day over 38 days) compared to placebo in healthy volunteers with moderate physical activity on muscle recovery, physical capacity, cardiorespiratory recovery, the perception of the arduousness of the effort, the variation in blood lactate levels before and after physical exercise, the perception of the intensity of post-exercise muscle pain (cramps), the body composition and Nicotinamide-Adenine Mononucleotide (NAD+) level in blood.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-12-10
• Study First Submitted QC: 2020-12-10
• Study First Posted: 2020-12-11
• Study Start: 2021-03-09
• Primary Completion: 2022-11-10
• Study Completion: 2023-05-30
• Status Verified: 2024-01
• Last Update Submitted: 2024-01-15
• Last Update Posted: 2024-01-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 131

Inclusion Criteria

• Body Mass Index ranging from 20 to 28 kg/m2(bounds included);
• Body weight between of 70 kg to 100 kg (including limits);
• Able to provide written informed consent to participate;
• Having a moderate level of physical activity according to the Global Physical Activity Questionnaire (GPAQ);
• Having a sport practice involving endurance or split races (including collective or individual sports) or cycling.
• Agreeing not to change their physical activity habits throughout the study;

Exclusion Criteria

• Having a mental state that does not allow them to give free and informed consent to participate in the study;
• Being taking regularly or have taken within the last month any medication or dietary supplement that may increase endurance, recovery, or physical capacity. In particular, the following drugs are strictly prohibited: beta-2 agonists such as salbutamol (Ventolin®), terbutaline (Bricanyl®), fenoterol (Berotec®), salmeterol (Serevent®) and formoterol (Foradil®) as well as corticosteroids;
• Having history of a recent (less than 3 months) lower extremity muscle injury;
• Presenting a depressive syndrome;
• Presenting, in the opinion of the investigator, any symptomatology, pathology or cardiovascular risk factors that are incompatible with the conduct of the study or with the performance of a stress test or that could influence the results of the study, and in particular: 1) an abnormal resting and/or stress ECG at the inclusion visit according to the investigator; 2) presence of abnormalities in the lipid balance (Total Cholesterol, Triglycerides, HDL, LDL), blood glucose, and/or hemodynamic parameters;
• Presenting an abnormal biological balance (Creatinine, Uric acid, Troponin, Alanine aminotransferase / Aspartate aminotransferase, Lactate dehydrogenase, Creatine Kinase, C-reactive protein, Transferrin, Bilirubin, Gamma Glutamyl transpeptidase, Cholesterol (EAL), Glycemia, Ionogram, Alkaline phosphatase );
• Being not be compliant with the constraints imposed by the protocol;
• Having an allergy or a contraindication to the components of the studied products;
• Being already involved in another clinical trial or being in the exclusion period of a previous clinical trial;
• Being unable to understand, speak and read French fluently;
• Being not affiliated with a health insurance company;
• Being vulnerable persons or persons deprived of liberty by a judicial or administrative decision;
• Consuming illegal psychotropic substances or having an alcohol consumption of more than 2 glasses of alcohol/wine per day.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NMN 500	Nicotinamide mononucleotide	NMN tablet (500 mg)
NMN 250	Nicotinamide mononucleotide	NMN tablet (250 mg)
Placebo	Placebo	NMN-free placebo tablet.

Primary Outcome Measures

Name	Time	Method
Evolution of muscle recovery	before and after 21 and 38 days of treatment	Wingate Anaerobic Test (WANT) preformed post-endurance test (at 85% maximum aerobic speed)

Secondary Outcome Measures

Name	Time	Method
Changes in physical capacity	before and after 21 and 38 days of treatment	physical capacity evaluated during an endurance test (at 85% maximum aerobic speed) by the maximum duration (time limit)
Changes in cardiorespiratory recovery	before and after 21 and 38 days of treatment	Measurement of blood pressure and heart rate at rest and at intervals of several minutes after the endurance test (at 85% maximum aerobic speed)
Changes in the body composition	before and after 21 and 38 days of treatment	fat mass, muscle mass, visceral fat, water mass determined by Bioelectrical Impedance Analysis (BIA)
Changes blood NAD+ levels	before and after 21 and 38 days of treatment	Evaluation of cellular NAD+ concentration in blood from baseline to the end of study
Changes in the perception of the arduousness of the effort	before and after 21 and 38 days of treatment	evaluated by the Borg scale during the endurance test (at 85% maximum aerobic speed)
Changes in the perception of the intensity of post-exercise muscle pain (cramps)	before and after 21 and 38 days of treatment	post-exercise muscular pain in evaluated using a 7 points numerical scale, 24, 48 and 72 hours after the endurance test
Changes in blood lactate levels before and after physical exercise	before and after 21 and 38 days of treatment	blood lactate levels before and after the endurance test (at 85% maximum aerobic speed)

Trial Locations

Locations (1)

CEN Nutriment; 🇫🇷 Dijon, France